These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9886458)

  • 21. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
    Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763
    [No Abstract]   [Full Text] [Related]  

  • 26. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].
    Kuwabara T
    Rinsho Shinkeigaku; 2002 Aug; 42(8):757-60. PubMed ID: 12701223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
    Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
    J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pergolide-associated valvular heart disease.
    Waller EA; Kaplan J
    Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F; Garbe E
    Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease.
    Kanovský P; Bares M; Pohanka M; Rektor I
    J Neurol; 2002 Jan; 249(1):112-4. PubMed ID: 11954860
    [No Abstract]   [Full Text] [Related]  

  • 35. Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.
    Crevits L; Versijpt J; Hanse M; De Ridder K
    Neuropsychobiology; 2000; 42(4):202-6. PubMed ID: 11096336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retroperitoneal fibrosis secondary to pergolide therapy.
    Fukae J; Tanaka S; Hattori N
    Intern Med; 2010; 49(15):1687. PubMed ID: 20686321
    [No Abstract]   [Full Text] [Related]  

  • 37. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
    Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
    Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sleep attacks and pergolide mesylate].
    García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
    Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.